Inactive Instrument

Highlights Protalix Biotherapeutics Inc TEL AVIV STOCK EXCHANGE

Equities

US74365A1016

Highlights

Unlock all the news: Be the first to know and act before the market!

Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Earnings Flash (PLX) PROTALIX BIOTHERAPEUTICS Reports Q1 Revenue $3.7M, vs. Street Est of $9.2M	05-10	MT
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06	CI
Earnings Flash (PBDA) PROTALIX BIOTHERAPEUTICS Reports Q3 Revenue $10.3M	11-06	MT
Earnings Flash (PBDA) PROTALIX BIOTHERAPEUTICS Reports Q2 Revenue $35.1M	07/08/23	MT
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/08/23	CI
Protalix Biotherapeutics, Inc. Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases	18/05/23	CI
Chiesi Global Rare Diseases and Protalix Biotherapeutics, Inc. Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease	10/05/23	CI
Protalix Biotherapeutics, Inc. and Chiesi Global Rare Diseases Announces European Commission Grants Marketing Authorization to PRX-102 (Pegunigalsidase Alfa) for the Treatment of Adult Patients with Fabry Disease	05/05/23	CI
Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23	CI
Earnings Flash (PBDA) PROTALIX BIOTHERAPEUTICS Reports Q1 Revenue $9.6M	04/05/23	MT
Protalix BioTherapeutics, Inc. Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout	21/03/23	CI
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23	CI
Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. Receives Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease	24/02/23	CI
Protalix BioTherapeutics' Joint Resubmission of Application for Fabry Disease Treatment Gets FDA Acceptance	05/12/22	MT
Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of A Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease	05/12/22	CI
Earnings Flash (PLX) PROTALIX BIOTHERAPEUTICS Reports Q3 Revenue $14.2M, vs. Street Est of $5.7M	14/11/22	MT
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease	14/11/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Protalix Biotherapeutics Inc TEL AVIV STOCK EXCHANGE

Equities

US74365A1016

Highlights

Filters